The vaccine adjuvants market, valued at USD 5.26 billion in 2025, is projected to grow to USD 5.51 billion in 2026 and USD 6.08 billion by 2035, representing a CAGR of 1.1% during the forecast period. Presently, an increasing number of vaccines under development are incorporating adjuvants in vaccines owing to various advantages offered by such agents, including improved adaptive response to a vaccine, guiding the type of adaptive response to produce the most effective forms of immunity for each...

The global molecular cloning market for kits is estimated to grow from $3.1 billion in 2025 to $3.6 billion in 2026 and $14.5 billion by 2035, representing a higher CAGR of 16.9% during the forecast period. Further, more than 3,200 patents and 4,000 research articles have been published for DNA cloning technologies in the past few years; this is indicative of the innovative efforts of the stakeholders engaged in molecular cloning market. Driven by the increasing demand for gene therapies and the...

The global cell migration and cell invasion assay market, valued at USD 1.6 billion in 2025, is projected to reach USD 1.8 billion in 2026 and USD 3.5 billion by 2035, representing a CAGR of 7.7% during the forecast period. Given their extensive utilization in various drug discovery, tumor study and screening applications, there has been a significant rise in the revenue generation potential associated with cell migration and cell invasion assay kits. The current cell migration and cell invasion...

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies for Bullous Pemphigoid, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of the forecasted therapies and the likely selling pric...

Cancer, a life-threatening disease, also has genetic origins, and is considered among the leading causes of death across the globe. In fact, the World Health Organization (WHO) has reported that close to 10 million cancer related deaths annually, across the world. As a result, this disease area is characterized by a significant unmet need for curative interventions; and therefore, considered among the most lucrative opportunity areas for biopharmaceutical developers. Currently, there are over 20...

Cancer, one of the leading causes of death worldwide, claimed close to 10 million lives annually Although there are several treatment options available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is difficult to achieve. In this context, immunotherapies, a relatively recent addition to the gamut of anticancer interventions, have demonstrated significant promise. Presently, the success rate for CAR T-cell therapies is estimated to...

In 2020, close to 340 million tons of meat was estimated to be produced worldwide. Compared to the early 1960s (~70 million tons), this represents almost a 500% increase. As a result, raising animals for slaughter is estimated to be responsible for close to 15% of global greenhouse gas emissions. Animal farming also requires large areas of land, for grazing, which is often the cause of deforestation efforts. In this context, it is worth highlighting that raising cattle for beef and lamb meat pro...

The women's digital health market is estimated to be worth $2.04 billion in 2022 and is expected to grow at compounded annual growth rate (CAGR) of 18.9% during the forecast period. Females constitute 49.6% of the world

The global aptamers market is estimated to grow from $0.92 billion in 2025 to reach $1.48 billion in 2026 and $12.78 billion by 2035, representing a higher CAGR of 27.0% during the forecast period. Over 100 clinical trials, along with several preclinical studies, have demonstrated the potential of aptamers as a safe and effective treatment modality, owing to their unique characteristics, such as high binding affinity and specificity. Given the various advantages, aptamer-based therapeutics in th...

The report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of GvHD.

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.

The report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Dravet syndrome.

The “Soft Tissue Sarcoma: Pipeline Review, Developer Landscape and Competitive Insights, 2022-2035” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of soft tissue sarcoma.

The report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Cryptococcosis.

The “Pompe Disease: Pipeline Review, Developer Landscape and Competitive Insights, 2025-2035” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Pompe Disease.